Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas posted May 13 fiscal 2007 net revenue of ¥177.4 billion ($1.7 billion), a 32 percent increase over the ¥131.3 billion ($1.3 billion) posted the previous fiscal year. For the present fiscal year however, the Tokyo-based company, which focuses in urology, immunology and inflammatory, diabetes, CNS/pain, infectious diseases and cancer, forecasts a 10.4 percent drop in net revenue to ¥159 billion ($1.518 billion). In a May 14 earnings call with investors and analysts, company president and CEO Masafumi Nogimori noted sales of immunosuppressant Prograf (tacrolimus) grew in each region, with global sales of ¥203 billion. However, the drug's substance patent expired in April. "Based on this, U.S. sales will decline by 5.5 percent," Nogimori said
Advertisement

Related Content

Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.
Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.
Astellas Tacrolimus Approval Remains At Bay
Astellas Tacrolimus Approval Remains At Bay
Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis
EMEA Recommends Approval For Astellas’ Mycamine
Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million
Advertisement
UsernamePublicRestriction

Register

SC068479

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel